ZymoGenetics

Biopharmaceutical Therapeuticszymogenetics.com

ZymoGenetics was a Seattle-based biotechnology company founded in 1981 that developed production systems for recombinant proteins and protein-based therapeutics. The company was acquired by Bristol-Myers Squibb circa 2010 and fully integrated into the parent.

Company typePublic
Founded1981
HeadquartersSeattle, United States
Headcount251–500
GTM typeB2B
OfferingHardware or Manufacturing

What ZymoGenetics does

ZymoGenetics was a Seattle-based biotechnology company founded in 1981 with an early focus on developing production systems for recombinant proteins. The company built specialized capabilities in protein-based therapeutics and operated with a workforce of 251–500 employees at its peak, previously trading on NASDAQ under the ticker ZGEN. Its business model centered on research and development of biopharmaceutical products, supported by multiple rounds of equity financing including a $100 million Deerfield-led round in June 2008 and a $97 million round in January 2010.

ZymoGenetics was acquired by Bristol-Myers Squibb (NYSE: BMY) circa 2010 and subsequently fully integrated into the parent company. Evidence of this integration includes the 404 status of the dedicated ZymoGenetics page on BMS's corporate website and the absence of any independent operating footprint. BMS operates globally across North America, Europe, Asia, Australia, and South America, and retains several acquired subsidiary brands (Mirati, Karuna, Celgene) alongside the now-defunct ZymoGenetics brand. As of the input data, ZymoGenetics has no active product, pricing, distribution, or marketing operations distinct from BMS, and its website URL (zymogenetics.com) is not described as functional. The firm was co-founded by Earl W. Davie, who established its foundational protein technology platform.

ZymoGenetics firmographics

Firmographics

Name: ZymoGenetics
Legal name: Bristol-Myers Squibb Company
Website: https://zymogenetics.com
Company type: Public
Founded year: 1981
Operating status: Acquired
Headcount range: 251–500 employees
Short description: ZymoGenetics was a Seattle-based biotechnology company founded in 1981 that developed production systems for recombinant proteins and protein-based therapeutics. The company was acquired by Bristol-Myers Squibb circa 2010 and fully integrated into the parent.
Ownership category
akta.pro rank

ZymoGenetics industry classification

Industry

Product category: Biopharmaceutical Therapeutics
NAICS: Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC: Biological Products, (No Disgnostic Substances) (2836)
akta.pro primary industry: Recombinant Protein Therapeutics (enzymes, hormones, growth factors) (HLAAAAAB)
akta.pro secondary industry: Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA)

Keywords

Recombinant protein therapeutics
Biopharmaceutical development
Protein-based medicines
Therapeutic protein production
Biotechnology research

Where ZymoGenetics is headquartered

Location

Headquarters

HQ city: Seattle
HQ country: United States
HQ region: North America

Markets served

ZymoGenetics business model

Business model

GTM type: B2B
Offering type: Hardware or Manufacturing
Cost components: Technology or R&D, Personnel, Operations

ZymoGenetics product offering

Product offering

Core offering

ZymoGenetics was a biotechnology company whose early focus was on the development of production systems for recombinant proteins used in therapeutic applications. Following its acquisition by Bristol-Myers Squibb in 2010, the entity was fully integrated into BMS operations, and the dedicated ZymoGenetics operations page on the BMS website now returns a 404 error, indicating no active standalone product offerings remain.

Differentiator

Problem solved

Functional benefit

Products and services

ZymoGenetics subsidiary brand

Companies that use ZymoGenetics

Customer profile

Ideal customer profiles1 record

ZymoGenetics technology and API

Technology

Technology focussed Yes

API detail

Has API: No
API docs
API detail

Core technology

AI maturity

App detail

ZymoGenetics partnerships and signals

Strategic signal

Recent moves4 records

Expansion highlights2 records

ZymoGenetics competitors and assessment

Company assessment

Market position

Competitive moat2 records

Key risks4 records

Key highlights5 records

Customer concentration

ZymoGenetics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ZymoGenetics leadership team

Management profile

Number of profiles

ZymoGenetics subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

ZymoGenetics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ZymoGenetics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ZymoGenetics

What does ZymoGenetics do?

Is ZymoGenetics a public or private company?

ZymoGenetics is a public company. It is classified as corporate owned and is currently acquired.

When was ZymoGenetics founded?

ZymoGenetics was founded in 1981. It employs 251 to 500 people.

Where is ZymoGenetics based?

ZymoGenetics is headquartered in Seattle, United States, in the North America region.

Does ZymoGenetics have an API?

No public API is recorded for ZymoGenetics.

What industry is ZymoGenetics in?

ZymoGenetics's product category is Biopharmaceutical Therapeutics. Its primary akta.pro industry code is HLAAAAAB, Recombinant Protein Therapeutics (enzymes, hormones, growth factors), with a secondary code of HLAAAAAA, Monoclonal Antibody Therapeutics (mAbs). Its NAICS code is 325414 and its SIC code is 2836.